MetaCap

Milestone Pharmaceuticals (MIST) vs Rafael (RFL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rafael (RFL) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 25.8% versus a loss of 84.5%. Over five years, RFL leads with a -84.2% price change compared with -93.8% for MIST. Rafael is the larger company by market cap ($48.0 million vs $46.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MIST-84.54%RFL-25.83%
+219%+60%-99%
Nov 21, 20251 yearNov 20, 2026
MIST-93.88%RFL-84.64%
+64%-19%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MIST versus RFL key metrics
MetricMISTRFL
Share price$0.3711$0.9197
Market cap$46.20M$47.99M
1-day change-7.06%+2.19%
YTD return-81.63%-22.06%
1-year return-84.54%-25.83%
5-year return-93.85%-84.19%
EPS (TTM)$-0.74$-0.58
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$874.00K
Revenue growth (YoY)—-4.69%
Net income (latest FY)$-63.06M$-29.64M
Operating margin—-3822.54%
Net margin—-3390.73%
52-week high$3.06$3.96
52-week low$0.362$0.781
Distance from 52-week high-87.87%-76.78%
Analyst consensusnone—
Avg. price target upside+1479.09%—
Average volume1.53M140.84K
Shares outstanding124.50M51.39M
Employees3821
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RFL has outperformed MIST by 58.7 percentage points over the past year.

About Milestone Pharmaceuticals

MIST stock →

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

MIST vs RFL FAQ

Which is bigger, Milestone Pharmaceuticals or Rafael?

Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $46.20M for Milestone Pharmaceuticals (MIST).

Which stock has performed better over the past year, MIST or RFL?

RFL returned -25.83% over the past 12 months, compared with -84.54% for MIST (price return, excluding dividends). Past performance does not predict future results.

Are Milestone Pharmaceuticals and Rafael in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons